Company Filing History:
Years Active: 2024
Title: Yoonjung Shin: Innovator in Cancer Treatment
Introduction
Yoonjung Shin is a prominent inventor based in Los Angeles, CA (US). She has made significant contributions to the field of immunology, particularly in the development of T cells with improved functionality for cancer treatment. Her innovative work has the potential to revolutionize therapeutic approaches to combat cancer.
Latest Patents
Yoonjung Shin holds 1 patent related to her groundbreaking research. The patent focuses on immune cells engineered to inhibit the endogenous expression of one or more of Blimp-1 and A20, and/or overexpress one or more of exogenous TCF7 and Bach2. This method of treating cancer involves administering these modified cells to enhance their effectiveness. Additionally, her patent outlines methods to increase the peak fold proliferation rate, killing efficiency, and induce cellular characteristics associated with the naïve phenotype of immune cells. This is achieved by introducing an exogenous construct encoding a CAR or a TCR while inhibiting the endogenous expression of Blimp-1 and A20.
Career Highlights
Yoonjung Shin is currently associated with Kite Pharma, Inc., a leading company in the field of cancer immunotherapy. Her work at Kite Pharma has positioned her as a key player in the development of innovative cancer treatments.
Collaborations
Yoonjung collaborates with notable colleagues, including Saikat Banerjee and Christopher Ecker. Their combined expertise contributes to the advancement of research in cancer therapies.
Conclusion
Yoonjung Shin's contributions to the field of immunology and cancer treatment are noteworthy. Her innovative approaches and patented methods hold promise for improving patient outcomes in cancer therapy.